Business, energy, technology, markets and global industry news from Business News Today

ViiV Healthcare

PharmaDeviceNews ViiV Healthcare
ViiV Healthcare’s two-drug Dovato regimen matched the three-drug Biktarvy regimen for viral suppression at Week 48 in the head-to-head VOGUE HIV study. Representative image.
Pharma & Biotech

ViiV Healthcare challenges three-drug HIV standard with positive Dovato VOGUE data

ViiV Healthcare’s VOGUE trial found Dovato non-inferior to Biktarvy at Week 48, sharpening the debate over two-drug first-line HIV care.

Read More
Pharma & Biotech

ViiV Healthcare’s Cabenuva and Dovato strategy looks like an ecosystem play as ultra long-acting candidates advance

ViiV Healthcare heads to CROI 2026 with ultra long-acting HIV data for VH4524184, VH4011499 and more. See what it changes next.

Read More
Representative image illustrating the rising focus on U.S. drug pricing reform, as pharmaceutical companies like GSK move to expand access to asthma and COPD medicines through lower costs and direct purchasing models.
Pharma & Biotech

GSK strikes deal with U.S. to lower asthma and COPD drug prices and avoid tariffs

GSK plc’s latest agreement with the United States Administration to lower the price of respiratory medicines, including its inhaled asthma and chronic obstructive pulmonary disease (COPD) portfolio, signals a shift in how global pharmaceutical companies are choosing to respond to increasing U.S. political pressure around drug affordability. The agreement, announced on December 22, 2025, satisfies

Read More